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Syndecan-1, a heparan sulfate proteoglycan, has an important
role in wound healing by binding several growth factors and
cytokines. As these processes are also crucial in damage and
repair after renal transplantation, we examined syndecan-1
expression in human control kidney tissue, renal allograft
protocol biopsies, renal allograft biopsies taken at indication,
and non-transplant interstitial fibrosis. Syndecan-1 expression
was increased in tubular epithelial cells in renal allograft
biopsies compared with control. Increased epithelial syndecan-
1 in allografts correlated with low proteinuria and serum
creatinine, less interstitial inflammation, less tubular atrophy,
and prolonged allograft survival. Knockdown of syndecan-1 in
human tubular epithelial cells in vitro reduced cell proliferation.
Selective binding of growth factors suggests that syndecan-1
may promote epithelial restoration. Bilateral renal ischemia/
reperfusion in syndecan-1–deficient mice resulted in increased
initial renal failure and tubular injury compared with wild-type
mice. Macrophage and myofibroblast numbers, tubular
damage, and plasma urea levels were increased, and tubular
proliferation reduced in the kidneys of syndecan-1 deficient
compared with wild-type mice 14 days following injury. Hence
syndecan-1 promotes tubular survival and repair in murine
ischemia/reperfusion injury and correlates with functional
improvement in human renal allograft transplantation.
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Renal allograft transplantation is the treatment of choice
for chronic kidney failure. Although significant advances
have been made in the limiting (hyper) acute renal allograft
rejection, chronic transplant dysfunction poses a serious risk
of renal allograft loss at months to years after transplantation.
Many factors are known to affect graft function and survival.
For example, perioperative ischemia/reperfusion injury (IRI)
causes severe damage to the tubular epithelial cells (TECs)
of the donor organ, and tubular injury due to ischemia
can persist into the chronic phase as a result of vascular
changes.1–4 The number and severity of immune-mediated
acute allograft rejection episodes, and especially chronic
transplant dysfunction, characterized by tubular atrophy,
interstitial fibrosis, and transplant glomerulopathy, can result
in graft loss. Clearly, repair of tubular damage is a crucial step
in restoration of renal function upon transplantation, and
the balance between functional repair of tubular epithelium
vs. chronic inflammation and nonfunctional scarring, i.e.,
fibrosis, is a dominant factor determining renal allograft
function in the long run.5
In previous studies, we showed that renal inflammatory
responses can be affected by changes in heparan sulfate
proteoglycans (HSPGs), as observed in experimental renal
IRI, as well as in primary human kidney diseases.6,7 HSPGs
are glycoconjugates that consist of a core protein to which a
number of linear carbohydrate side chains (glycosaminogly-
cans; GAGs) are linked.8,9 HS-GAG chains are typically very
heterogeneous because of the coordinated action of various
enzymes, which modify the alternating glucuronic acid and
N-acetylglucosamine residues, resulting in varying degrees of
sulfation and epimerization. HSPGs are involved in diverse
biologically processes, including angiogenesis, wound heal-
ing, development, and inflammation.10–12 HSPGs exert their
functions predominantly by binding and presenting growth
factors, chemokines, and cytokines, and facilitating adhesion
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of inflammatory cells by binding to the leukocyte adhesion
molecule L-selectin.6,8,13 Binding of these factors to HSPGs is
mediated by the HS-GAG chains, and is dependent on the
chemical fine structure of the GAGs.8,14 We previously
showed that within 24 h after renal IRI, HSPGs expressed at
the abluminal side of peritubular capillaries are induced to
bind L-selectin and the monocyte chemoattractant protein-1,
and that these HSPGs facilitate monocyte extravasation.6
Similar changes were observed in human primary kidney
diseases associated with interstitial inflammation.7 In addition,
we noted an increased expression of the cell-surface HSPG
syndecan-1 on TECs in biopsy specimens of proteinuric
patients.7 Syndecan-1 is a transmembrane HSPG involved in
re-epithelialization during wound healing and inflamma-
tion.10,15,16 Earlier studies have implicated syndecan-1 in
epithelial differentiation.17,18 These processes are also very
relevant in the context of renal allograft transplantation, i.e.,
inflammation as a result of IRI and donor–acceptor antigenic
mismatching, and tubular re-epithelialization and differentia-
tion to restore the damaged tubular epithelium after IRI.
Indeed, a recent review by Venkatachalam et al.19 posed the
hypothesis that failure of tubular epithelial differentiation and
therefore impaired tubular repair upon larger or smaller acute
kidney injury episodes may have a significant role in the
progression of kidney disease.
On the basis of this background, we hypothesized that
syndecan-1 is involved in tubular survival and repair upon
renal transplantation. We examined expression of syndecan-1
in human renal allograft biopsies, including protocol biopsies
and biopsies taken at indication, and correlated syndecan-1
expression to allograft function and binding of relevant
growth factors. To directly study the functional role of
syndecan-1, we studied the effect of syndecan-1 knockdown
(in vitro) on TEC proliferation. In addition, we performed
bilateral renal IRI in syndecan-1 vs. wild-type (WT) mice and
studied functional and histological outcome. On the basis of
our data, we propose that syndecan-1 is involved in
determining the balance between nonfunctional scarring
and functional repair, and could be a novel marker indicating
prolonged renal allograft survival.
RESULTS
Increased syndecan-1 expression on TECs in a subset of renal
allograft biopsies
In 13 out of 14 control kidneys, weak staining for syndecan-1
protein was detected in a limited percentage of TECs (Figure
1a and b). In contrast, very prominent TEC syndecan-1
staining was observed in all Tx-protocol biopsies (taken
according to protocol at 1 year after transplantation), and a
large subset of Tx-MHA (minor histological alterations,
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Figure 1 | Increased syndecan-1 expression on tubular epithelial cells (TECs) in a subset of renal allograft biopsies.
(a) Immunostaining of human control kidney and minor histological alteration (Tx-MHA) biopsy for syndecan-1 protein expression.
G, glomerulus, bar¼ 50mm. (b) Scoring for syndecan-1–positive TECs in control kidney, Tx-protocol, Tx-MHA, acute allograft rejection
biopsies (Tx-AR), interstitial inflammation/tubular atrophy biopsies (Tx-IFTA), and nonTx-IFTA biopsies. *Kruskal–Wallis test Po0.001; Po0.05
control vs. Tx-protocol, Tx-MHA, Tx-AR, and Tx-IFTA; Po0.05 nonTx-IFTA vs. Tx-IFTA (P-values adjusted for multiple comparison using
Bonferroni). (c) Scoring for the percentage of syndecan-1–positive TECs in biopsies with different types/grades of AR according to the
BANFF classification; not statistically different (Kruskal–Wallis). (d) Scoring for the percentage of syndecan-1–positive TECs in biopsies
diagnosed as Tx-IFTA grades I, II, and III according to the BANFF classification; not statistically different (Kruskal–Wallis).
652 Kidney International (2012) 81, 651–661
or ig ina l a r t i c l e JWAM Celie et al.: Syndecan-1 in renal allografts
borderline interstitial inflammation and/or borderline tubu-
lar atrophy, and/or borderline intersitital fibrosis, no tubulitis
or vasculopathy), acute allograft rejection biopsies (Tx-AR),
and Tx-IFTA (interstitial inflammation/tubular atrophy
biopsies; Figure 1b). This increased syndecan-1 staining
showed distinct localization to the basolateral side of TECs
(Figure 1a). Syndecan-1 staining was not observed in
glomeruli or interstitial vasculature in any of the biopsies
examined.
Within the Tx-AR and Tx-IFTA group, the percentage of
syndecan-1–positive TECs was heterogeneous throughout
the different pathological types/grades (Figure 1b–d), and
there was a trend towards a lower percentage of syndecan-
1–positive TECs in the more severe Tx-IFTA grades, which
was, however, not statistically different. To further character-
ize the pathological status of transplant biopsies included in
this study, we scored for interstitial inflammation, tubulitis,
tubular atrophy, C4d status, glomerulosclerosis, vasculo-
pathy, acute tubular necrosis, epithelial vacuolization, and
interstitial fibrosis according to the BANFF criteria (as
indicated in Supplementary Table S1 online). Correlation
analysis across the whole panel of biopsies revealed that
increased TEC syndecan-1 is associated with lower scores for
interstitial fibrosis (Spearman’s r¼0.356, Po0.001), inter-
stitial inflammation (Spearman’s r¼0.305, Po0.005), and
tubular atrophy (Spearman’s r¼0.262, Po0.01).
Increased TEC syndecan-1 is associated with better graft
function and prolonged allograft survival
We next examined whether the percentage of syndecan-
1–positive TECs was associated with clinical parameters,
including time between transplantation and biopsy (time Tx
to biopsy), markers for renal function (proteinuria, serum
creatinine), and graft survival. A negative correlation was
found between the percentage of syndecan-1–positive TECs
and time Tx to biopsy (Spearman’s r¼0.254, P¼ 0.016;
analyzed over Tx-protocol, Tx-MHA, Tx-AR, and Tx-IFTA
groups together), indicating that a longer time between
transplantation and biopsy is associated with lower percent-
age of syndecan-1–positive TECs. However, in subgroups of
Tx-MHA and Tx-IFTA, which were matched according to
similar time Tx to biopsy (Figure 2a; time Tx to biopsy
between 32 and 288 weeks; Tx-MHA n¼ 6, median 216
weeks, range 32–288 vs. Tx-IFTA n¼ 12, median 188 weeks,
range 40–265), the percentage of syndecan-1–positive TECs
was significantly higher in the Tx-MHA subgroup compared
with the Tx-IFTA subgroup (Figure 2b; P¼ 0.032). Within
the Tx-MHA or Tx-IFTA groups, no statistical correlation
was observed between time Tx to biopsy and the percentage
of syndecan-1–positive TECs (Spearman’s r¼ 0.150,
P¼ 0.495 for Tx-MHA; Spearman’s r¼ 0.193, P¼ 0.315 for
Tx-IFTA). These data suggest that TEC syndecan-1 expres-
sion is initially increased upon transplantation and decreases
over time, although expression remains higher over time in
biopsies with relatively mild histological abnormalities (e.g.,
Tx-MHA).
We next investigated whether TEC syndecan-1 expression
in the allografts was related to clinical markers indicative
of allograft function (determined at time of biopsy). A statis-
tically significant negative correlation was found between
the percentage of syndecan-1–positive TECs and proteinuria
(as indicated in Figure 2c; Spearman’s r¼0.315, Po0.005)
and serum creatinine (as indicated in Figure 2d; Spearman’s
r¼0.334, Po0.001; both analyzed across Tx-protocol, Tx-
MHA, Tx-AR, and Tx-IFTA groups). These data demonstrate
that increased TEC syndecan-1 expression is associated with
improved renal allograft function.
In control kidneys, 13 out of 14 biopsies showed
syndecan-1 expression in 30% or less TECs, which we there-
fore regarded as a relevant cutoff for survival analysis. There
was a statistically significant correlation between an increased
percentage of syndecan-1–positive TECs and renal allograft
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Figure 2 | Increased tubular epithelial cell (TEC) syndecan-1
expression is associated with time Tx to biopsy, renal
allograft function, and survival. (a) Subgroups of minor
histological alteration (Tx-MHA) and Tx-IFTA were matched based
on similar time Tx to biopsy. (b) Scoring for the percentage of
syndecan-1–positive TECs in Tx-MHA and Tx-IFTA subgroups;
*P¼ 0.032 (Mann–Whitney U-test). (c and d) Graphical
representation of the association between TEC syndecan-1
and proteinuria (c) and serum creatinine (d). (e) Kaplan–Meier
curve showing the association between TEC syndecan-1 and
allograft survival. o30% TEC syndecan-1 n¼ 22 with 13 events,
430% TEC syndecan-1 n¼ 68 with 11 events. Log-rank test
Po0.001.
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survival (Figure 2e;o30% TEC syndecan-1 mean survival¼
405 weeks, 430% TEC syndecan-1 mean survival¼ 862
weeks; log-rank test Po0.001). As expected, increased
proteinuria was associated with decreased graft survival
(log-rank test P¼ 0.039).
Together, these data show that TEC syndecan-1 is differen-
tially expressed in renal allografts, and increased TEC
syndecan-1 is associated with better renal allograft function
and prolonged graft survival.
Silencing of syndecan-1 in TEC cell line results in reduced
proliferation
We next examined the effect of short hairpin RNA (shRNA)-
mediated silencing of syndecan-1 in the human TEC cell
line HK-2 on short-term in vitro re-epithelialization and
more long-term proliferation. As shown in Figure 3a,
shRNA-mediated silencing of syndecan-1 (synd1-shRNA)
reduced cell-surface syndecan-1 expression to background
levels, whereas transfection with a control vector did not
affect syndecan-1 expression. In the standardized scratch
assay, no difference was observed between control vector
and synd1-shRNA TECs in short-term re-epithelialization
(Figure 3b and c). However, the more long-term proliferation
of synd1-shRNA TECs was significantly reduced com-
pared with control vector TECs (Figure 3d). Together,
these data show that, although knockdown of syndecan-1
in TECs does not affect short-term (likely predominantly
migration-induced) in vitro re-epithelialization, syndecan-1
expression seems to be a prerequisite for proper TEC
proliferation.
Increased TEC syndecan-1 shows specific binding with
heparin-binding EGF-like growth factor (HB-EGF) and
anti-HS monoclonal antibody (mAb) 10E4, but not fibroblast
growth factor (FGF)-2 and the anti-HS mAbs JM-403,
JM-13, and HK249
Knowing that HSPGs, including syndecan-1, can be modified
to present growth factors depending on cellular activa-
tion status, we explored whether the association between
syndecan-1 and TEC proliferation could be attributed to
growth factor binding. We chose to use FGF-2 (basic FGF)
and HB-epidermal growth factor (EGF), which are both
known to bind HSPGs,20–22 although possibly with differ-
ences in GAG-chain requirements.20–23 In an enzyme-linked
immunosorbent assay–type binding assay, we were able to
detect dose-dependent binding of FGF-2 and HB-EGF to a
heparin-albumin coating, which is used as a model molecule
for HSPGs (heparin is a highly sulfated HS-GAG chain;
Figure 4a). As shown in Figure 4b and Table 1, no basolateral
FGF-2 binding was observed in Tx-MHA biopsies despite
high syndecan-1 expression. Limited basolateral TEC binding
of FGF-2 was observed in one Tx-IFTA biopsy (Table 1),
and binding of FGF-2 to interstitially infiltrated cells was
observed in a number of biopsies (predominantly Tx-IFTA
and nonTx-IF, likely representing binding to heparin-
containing mast cells; not shown). When incubation of
FGF-2 was omitted no staining was observed, indicating that
binding of the exogenously added FGF-2 was detected rather
than endogenously present FGF-2 (not shown). Although
FGF-2 is a prototypic HSPG-binding growth factor, it is also
a pro-fibrotic growth factor, and therefore increased binding
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Figure 3 | Silencing of syndecan-1 reduces tubular epithelial cell (TEC) proliferation in vitro. (a) Knockdown of cell-surface syndecan-1
expression on the human TEC cell line HK-2 transfected with syndecan-1–specific short hairpin RNA (shRNA) (synd1-shRNA) compared
with control vector as shown by flow cytometry. (b and c) Knockdown of syndecan-1 does not affect short-term re-epithelialization of
HK-2 cells in a standardized scratch assay. Representative photographs (b), mean and s.d. of five separate experiments (c). (d) Reduced
proliferation of synd1-shRNA-transfected HK-2 cells as determined by the MTT assay. Mean and s.e.m. of five separate experiments,
*P¼ 0.013 (Student’s t-test).
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and expression in the renal allograft could be harmful/
disadvantageous. We therefore also examined binding of
HB-EGF, an epithelial survival factor, which is associated
with renal epithelial repair and is expressed in the regenera-
tion phase upon renal injury.24,25 As shown in Figure 4b and
Table 1, prominent binding of HB-EGF to the basolateral side
of TECs was observed most dominantly in the Tx-MHA
group, although it was also observed to different extents in
control tissue, Tx-IFTA, and nonTx-IF. Pretreatment of
Tx-MHA tissue sections with heparitinase I, an enzyme that
specifically degrades HS-GAG chains, completely diminished
HB-EGF binding to TECs, showing that HB-EGF binds to
basolateral TEC HSPGs (Figure 4c).
To explore the structural characteristics of tubular
epithelial HS in more detail, we also evaluated four different
anti-HS mAbs, namely JM-403, JM-13, 10E4, and HK249.
The various epitope requirements of these anti-HS mAbs
have been detailed elsewhere (see Materials and Methods
section). All four anti-HS mAbs stained subsets of renal
basement membranes; however, 10E4, in addition, stained
TECs in a basolateral manner in a number of biopsies.
Subgroup analysis revealed a close colocalization of anti-HS
mAb 10E4 and syndecan-1 (Table 1 and Figure 5). Together,
our data show increased binding of HB-EGF, but not FGF-2,
to basolateral TEC HSPGs, colocalizing with syndecan-1 and
10E4 HS expression, in a subset of renal allograft biopsies.
Syndecan-1–positive tubules, however, failed to bind with
FGF-2, and anti-HS mAbs JM-403, JM-13, and HK249. These
data highlight two levels of regulation by which the cells
modulate growth factor affinity, namely syndecan-1 protein
expression and the formation of specific sulfation motifs in
the HS polysaccharide side chains.
Syndecan-1–deficient mice are more susceptible to renal
IRI and show repair skewed to fibrosis
To determine the in vivo importance of syndecan-1 in renal
IRI, we next performed bilateral warm IRI in syndecan-
1–deficient mice.16,26 Anticipating a more severe phenotype
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Figure 4 | Specific binding of heparin-binding EGF-like growth
factor (HB-EGF), but not fibroblast growth factor (FGF)-2,
to basolateral tubular epithelial cell (TEC) heparan sulfate
proteoglycans (HSPGs) in minor histological alteration
(Tx-MHA) biopsies. (a) Dose-dependent binding of HB-EGF and
FGF-2 to heparin–albumin in vitro. (b) Binding of FGF-2 (left)
or HB-EGF (right) to control kidney (upper panels) and Tx-MHA
biopsies (lower panels). (c) Basolateral TEC binding of HB-EGF in
Tx-MHA binding is lost after pre-incubation of a sequential tissue
section with heparitinase I. G, glomerulus, bar¼ 50 mm.
Table 1 | Scoring for TEC syndecan-1 protein expression and
binding of FGF-2, HB-EGF, and anti-HS mAb 10E4 in a subset
of renal biopsies
Case Diagnosis Syndecan-1a
FGF-2
bindinga
HB-EGF
bindinga
Anti-HS
mAb 10E4a
1 Control 5 0 5 nd
2 Control 20 0 30 nd
3 Control 10 0 0 nd
4 Control 0 nd 0 8
5 Control 20 nd nd 46
6 Control 5 nd nd 10
7 Control 30 nd nd 3
8 Tx-MHA 80 0 70 nd
9 Tx-MHA 60 0 70 72
10 Tx-MHA 90 0 80 nd
11 Tx-MHA 80 0 nd 77
12 Tx-MHA 80 0 40 73
13 Tx-MHA 90 nd nd 82
14 Tx-IFTA 60 0 30 53
15 Tx-IFTA 30 0 0 1
16 Tx-IFTA 20 10 10 13
17 Tx-IFTA 0 0 0 nd
18 NonTx-IFTA 10 0 0 2
19 NonTx-IFTA 30 0 30 22
20 NonTx-IFTA 60 0 0 nd
21 NonTx-IFTA 60 nd nd 36
Abbreviations: FGF, fibroblast growth factor; HB-EGF, heparin-binding EGF-like
growth factor; HS, heparin sulfate; mAb, monoclonal antibody; nd, not determined;
TEC, tubular epithelial cell; Tx-IFTA, interstitial inflammation/tubular atrophy;
Tx-MHA, minor histological alteration.
aPercentage of TECs positive for expression/binding.
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in syndecan-1/, we used a relatively mild IRI model
(25min bilateral warm ischemia, followed by bilateral
reperfusion). Induction of syndecan-1 in the WT mice was
evidenced from day 1 onward, which by definition was not
observed in the syndecan-1 KO mice (Figure 6a–e).
Compared with WTmice, syndecan-1/ proved to be more
susceptible to IRI-induced renal damage (Figures 6 and 7).
At day 1 after IRI, plasma creatinine and ureum levels were
significantly increased in syndecan-1/ compared with WT
mice (Figure 6f and g). Histologically, clearly more tubular
damage was observed in syndecan-1/ kidneys at day 1 after
IRI (Figure 7a and c). Interestingly, tubular damage appeared
to remain constant over time in syndecan-1/ kidneys,
whereas damage was largely restored in WT kidneys at day 14
after IRI (Figure 7a and c). By Ki67 staining, we evaluated the
proliferative response of the tubular epithelium both in WT
and syndecan-1 KO mice. Although there is quite some
proliferation at day 3 after I/R (not different between both
groups), at day 7 and 14 of the regeneration phase the
syndecan-1 KO mice revealed lower proliferation rates
compared with the WT (day 14: P¼ 0.0411; Figure 7b).
Both macrophages and myofibroblasts are known to have an
important role in renal IRI damage/repair responses. We
therefore quantified the amounts of these cells by staining for
F4/80 (monocytes/macrophages) and a-smooth muscle actin
(myofibroblasts). As shown in Figure 7d, monocytes/macro-
phages steadily accumulated in syndecan-1/ compared
with WT kidneys. Interestingly, also the amount of
myofibroblasts was increased in syndecan-1/ compared
with WT kidneys at day 14 after IRI (Figure 7e).
Together, these data show that syndecan-1/ mice have
impaired renal function and increased tubular damage upon
renal IRI compared with WT mice. In addition, our data
indicate that tubular damage is restored less efficiently in
syndecan-1/ mice, and repair mechanisms may be skewed
toward fibrosis rather than restoration of tubular epithelium.
DISCUSSION
In this study, we show that syndecan-1 protein expression
is increased on the basolateral side of TECs after renal
transplantation and that the percentage of syndecan-1–posi-
tive TECs is significantly associated with better allograft
function and survival. We provide evidence that syndecan-1
is involved in TEC proliferation, and that binding of the
growth factor HB-EGF to TEC HSPGs is increased on the
basolateral side of TECs that also express syndecan-1. Finally,
we show that syndecan-1–deficient mice show more impaired
renal function and increased tubular damage associated
with reduced tubular repair in an experimental IRI model.
On the basis of our data, the role of syndecan-1 in the renal
epithelium may be similar to its role in dermal wound
healing.10,16 Indeed, we show that shRNA-mediated knock-
down of syndecan-1 expression in a TEC cell line significantly
reduces cell proliferation, affirming a role of syndecan-1 in
tubular re-epithelialization and repair. The involvement of
HB-EGF in TEC proliferation and renal epithelial repair
has been proposed earlier.24,25 Moreover, in a murine I/R
experiment we show that syndecan-1 promotes survival
(day 1) and proliferation/repair (day 14) of injured epithelial
cells, probably by functioning as co-receptors for survival/
growth factors such as hepatocyte growth factor, stromal-
derived factor, and HB-EGF.
Tubular induction of syndecan-1 likely reflects a certain
degree of dedifferentiation of the tubular cells to be respon-
sive after transplantation and permanent immunological
attack. Thus, renal tubular syndecan-1 expression probably
reflects a meaningful early epithelial–mesenchymal transition
response and mirrors syndecan-1 expression of the develop-
ing kidney.18 The presence of syndecan-1 on epithelial cells
brings the cells in a mobilized condition, now able to respond
effectively to growth factors such as HB-EGF. We speculate
that the loss of syndecan-1 in a number of transplantation
biopsies is because of further dedifferentiation and/or more
advanced epithelial–mesenchymal transition. These fully
dedifferentiated epithelial cells are not able to respond to
survival/growth factors anymore and will contribute to
chronic inflammation and IFTA. In our opinion, this inter-
pretation nicely corresponds to the concept of Venkatachalam
et al.19 that prolonged deep dedifferentiation of tubular cells
contributes to progression in chronic kidney disease. Our
data are also in line with the findings of Halloran et al.5 who
showed that impaired renal function in transplantation
biopsies is correlated with increased expression of tissue
injury gene sets and decreased expression of kidney trans-
cripts, indicating dedifferentiation of renal epithelial cells. We
thus conclude that the tubular induction of syndecan-1
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Co
nt
ro
l
Tx
-M
H
A
Anti-HS mAb 10E4
Figure 5 | Specific binding of anti-HS monoclonal antibody
(mAb) 10E4 in syndecan-1–positive biopsies. Staining of
syndecan-1 (left) and HS 10E4 epitope (right) in control kidney
(upper panel) and minor histological alteration (Tx-MHA) biopsy
(lower panel). Note the absence of syndecan-1 and 10E4 HS
staining in control tissue, whereas 10E4 HS positivity colocalizes
with basolateral syndecan-1 in representative Tx-MHA biopsy.
Bar¼ 50 mm.
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reflects a physiological response of the epithelium in order to
maintain/restore tubular integrity and regeneration/repair.
The mechanism behind increased expression of syndecan-1
protein was not specifically addressed in this study. There
are indications that syndecan-1 transcription can be regu-
lated by the proinflammatory transcription factor nuclear
factor-kB, as well as by an FGF-inducible response element
located upstream of the syndecan-1 promoter.27–29 Both
pathways are relevant in the context of renal transplanta-
tion.30,31 Furthermore, both transforming growth factor-b
and EGF have been shown to induce syndecan-1 mRNA
expression in vitro, and expression/activation of these factors
is enhanced upon renal transplantation, although especially
transforming growth factor-b has been associated with
fibrosis and EGF with proliferation.28,32–34 Apart from
transcriptional regulation, increased staining for syndecan-1
protein could be a result of reduced syndecan-1 shedding
from the cell surface.
From a clinical point of view, it would be interesting to
assess whether syndecan-1 concentration and binding
properties in urine of patients after renal allograft transplan-
tation are of diagnostic value to predict allograft status and
survival (unpublished data, van den Born et al.). In addition,
as immunosuppressive drugs used in the context of renal
transplantation are typically anti-proliferative, it would be
interesting to investigate their effect on syndecan-1 expres-
sion and/or growth factor binding.
As far as we know, syndecan-1 is the first tubular
marker that is positively associated with graft function and
survival. Other tubular markers such as KIM-1 (refs 35,36)
and NGAL37 or typical tubular EMT markers such as
vimentin and S100A4 (ref. 38) are negatively associated
with graft function and graft loss. Therefore, larger studies
with protocol biopsies have to show whether tubular
syndecan-1 might be a novel independent, prognostic
marker able to predict graft function and survival in the
long term.
In conclusion, our data provide evidence for a role of
syndecan-1 in tubular epithelial survival and repair in the
renal allograft. We propose that syndecan-1 can help shift the
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balance in the renal allograft towards functional restoration,
rather than nonfunctional scarring (fibrosis).
MATERIALS AND METHODS
Patient characteristics and histopathology
Renal allograft biopsies used in this study included protocol biopsies
taken at 1 year after transplantation (n¼ 9), or taken upon indica-
tion, diagnosed according to the BANFF criteria,39–42 representing
minor histological alterations (Tx-MHA, n¼ 27; borderline inter-
stitial inflammation and/or borderline tubular atrophy and/or
borderline intersitital fibrosis, no tubulitis or vasculopathy), acute
allograft rejection (AR, n¼ 23), transplants with interstitial fibrosis and/
or tubular atrophy (Tx-IFTA, n¼ 38; includes chronic allograft rejection
(n¼ 6)), and non-transplant interstitial fibrosis (non-Tx IF, n¼ 20).
Control kidney tissue included histologically normal tissue from kidneys
removed because of renal carcinoma (n¼ 12) and donor kidneys
unused because of anatomical issues (n¼ 2). Patient characteristics are
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summarized in Table 2. All patients with a renal allograft used
standard immunosuppressive regimens according to the institu-
tional guidelines. All procedures and use of anonymized tissue were
performed according to the the national ethical guidelines.
Diagnosis and scoring were performed by an experienced nephro-
pathologist according to the BANFF classification of renal allograft
pathology, in which the cell-mediated component of AR is classified
based on significant interstitial infiltration with foci of tubulitis
(Type IA/B), signs of intimal arteritis (Type IIA/B), or transmural
arteritis potentially accompanied by fibrinoid changes and medial
smooth muscle cell necrosis (Type III), and the severity of Tx-IFTA
is graded based on the amount of interstitial fibrosis and tubular
atrophy (Grade I; mild, Grade II; moderate, Grade III, severe). Data
on interstitial inflammation, tubulitis, tubular atrophy, acute
tubular necrosis, epithelial vacuolization, interstitial fibrosis,
vasculopathy, global glomerulosclerosis, and C4d staining (anti-
human polyclonal, Biomedica, Vienna, Austria) per diagnosis group
are provided in Supplementary Table S1 online.
Renal biopsy immunofluorescence and scoring
Formalin-fixed, paraffin-embedded archival renal tissue was used.
Staining for syndecan-1 (CD138; Serotec, Oxford, UK) and anti-HS
mAbs JM-403,43 JM-13,44 10E4 (ref. 45; Seikagaku, Tokyo, Japan), and
HK249 (ref. 46; Seikagaku) was performed after microwave-citrate
antigen retrieval by incubating appropriate dilutions of primary anti-
bodies for 1h at room temperature (RT; 20 1C), followed by incubation
of AlexaFluor-labeled anti-mouse IgG and anti-rabbit IgG secondary
antibodies (Molecular Probes, Invitrogen, Grand Island, NY) for
45min at RT. Binding experiments were conducted by incubating
excess amounts of recombinant human FGF-2 (2.5mg/ml; Peprotech,
Rocky Hill, NJ) or HB-EGF (2.5mg/ml; R&D Systems, Minneapolis,
MN) on tissue sections for 2 h at RT, followed by anti-human basic
FGF (Sigma-Aldrich, St Louis, MO) or anti-human HB-EGF (R&D
Systems) for 1 h, and AlexaFluor-labeled anti-mouse IgG secondary
antibodies for 45min at RT. Isotype-matched nonrelevant antibodies
served as background controls and proved to be negative. In some
experiments, tissue sections were pretreated with heparitinase I (0.05U/
ml; EC4.2.2.8; Seikagaku) in acetate buffer (50mmol/l C2H3O2Na,
5mmol/l CaCl2K2H2O, 5mmol/l MgCl2K6H2O, pH 7.0) for 1 h at
37 1C. Sections were examined using a Nikon Eclipse E800 fluorescence
microscope (Nikon, Tokyo, Japan) with digital camera using identical
microscopy conditions and exposure time for different samples. Stainings
were scored as % of TECs involved in cortical regions of biopsies
(typically 5–10 visual fields per biopsy), or non-biopsy tissues (15 visual
fields;  200 original magnification) without knowledge of diagnosis.
Cell culture
The human TEC cell line HK-2 (ref. 47) was kindly provided by Dr C van
Kooten, Leiden University Medical Center, Leiden, the Netherlands. Cells
were cultured in Dulbecco’s modified Eagle’s medium/F-12 (Gibco,
Grand Island, NY/Invitrogen) supplemented with 5mg/ml insulin, 5mg/
ml transferrin, 5ng/ml selenium, 36ng/ml hydrocortisone, 10ng/ml EGF
(Sigma-Aldrich), 50U/ml penicillin, 50mg/ml streptomycin, and 2mmol/l
L-glutamine (Cambrex, East Rutherford, NJ).
shRNA silencing
shRNAs targeting syndecan-1 (synd1-shRNA; target sequence 30-
GGTGCTTTGCAAGATATCA-50) and Renilla luciferase (control
vector; target sequence 30-AAACATGCAGAAAATGCTG-50) were
cloned into the pTER expression vector (kindly provided by
Professor H Clevers, Hubrecht Laboratory, Centre for Biomedical
Genetics, Utrecht, the Netherlands). HK-2 cells were transfected
with synd1-shRNA vector or control vector using Lipofectamine
(Invitrogen) according to the manufacturer’s protocol and selected
based on zeocine resistance.7 Knockdown of syndecan-1 expression
was determined by flow cytometry. Cells were detached using
EDTA-mix (10mmol/l EDTA, 150mmol/l NaCl, 6mmol/l KCl,
1.2mmol/l KH2PO4, 20mmol/l Hepes, 5mmol/l glucose, 0.5%
bovine serum albumin; pH 7.4), washed with phosphate-buffered
saline (PBS)/0.5% bovine serum albumin, and incubated with anti-
syndecan-1 (CD138) antibody in PBS/0.5% bovine serum albumin
(30min on ice). After washing, cells were incubated with FITC-
labeled anti-mouse IgG (30min on ice), washed, and analyzed
(FACSCalibur, Becton Dickinson, Franklin Lakes, NJ). Nonrelevant
mouse IgG served as isotype control.
Standardized scratch assay
Control vector or synd1-shRNA HK-2 cells were grown to
confluency in a 24-well plate. A standardized scratch was made in
all wells, and digital images were taken at indicated time points
using a time-lapse microscopy stage (37 1C; 5% CO2). Scratch area
was calculated using the AnalySIS (SIS Pro) software, Bethesda, MD.
MTT assay
Control vector or synd1-shRNA HK-2 cells were seeded in a 96-well
plate at 6000 cells/well. Cell proliferation was determined at
Table 2 | Patient characteristics
Diagnosis n Age (years) Sex (M/F)
Time Tx to
biopsy (weeks)
MAP
(mmHg)a
Serum creatinine
(lmol/l)a
Proteinuria
(g/24h)a
Control 14 67 (29–84) 9/3b
Tx-protocol 9 51 (32–66) 7/2 50 (45–53)* 104 (93–129) 102 (47–115) 0.2 (0–0.7)
Tx-MHA 25 48 (18–70) 19/6 3 (1–288) 101 (74–120) 222 (105–1229)** 0.3 (0–1.7)***
Tx-AR 28 45 (25–66) 16/12 2 (0.4–1248) 99 (62–137) 252 (127–1021)** 0.4 (0–11.3)***
Tx-IFTA 33 43 (11–69) 20/13 337 (12–1092)* 106 (80–153) 276 (125–730)** 1.6 (0–9.4)****
NonTx-IFTA 20 57 (20–79) 10/10 104 (84–133) 394 (80–632)** 1.1 (0.3–11.6)****
Abbreviations: MAP, mean arterial pressure; Tx-AR, acute allograft rejection biopsy; Tx-IFTA, interstitial inflammation/tubular atrophy; Tx-MHA, minor histological alteration.
Values are expressed as median and range.
aDetermined at the time of biopsy.
bNo data were available from two donor kidneys.
*Po0.05 Tx-protocol compared with Tx-AR Po0.05 Tx-IFTA compared with Tx-MHA and Tx-AR.
**Po0.005 compared with Tx-protocol.
***Po0.05 compared with Tx-IFTA and nonTx-IFTA.
****Po0.001 compared with Tx-protocol.
Kruskal–Wallis test with pairwise multiple comparisons (adjusted P-values).
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indicated time points by adding 10 ml MTT (5mg/ml; 3-[4,5-
dimethylthiazol-2-yl]-2,4 diphelnyltetrazolium bromide) per well
and incubating for 2 h at 371C. The supernatant was removed,
100ml/well dimethyl sulfoxide/glycine (7:1 v/v) was added to
dissolve the formed formazan crystals, and absorbance at 540 nm
was measured. Data are expressed as %MTT activity, with input at
t¼ 0 set at 100%.
Enzyme-linked immunosorbent assay-based growth factor–bind-
ing assay
Nunc MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were
coated overnight with 2.5 mg/ml heparin–albumin (Sigma, St Louis,
MO) in PBS. After blocking (PBS/5% bovine serum albumin; 2 h
RT), wells were incubated for 2 h at RT with indicated concentra-
tions of FGF-2 or HB-EGF in blocking buffer. Wells were washed
(PBS/0.05%Tween-20) and incubated with anti-human basic FGF or
anti-human HB-EGF diluted in blocking buffer. After washing, wells
were incubated with biotinylated anti-mouse IgG (1 h RT) and
streptavidin–peroxidase (30min RT) in blocking buffer. Wells were
extensively washed and substrate solution (3,3’,5,5’-tetramethylben-
zidine) was incubated for 15min at RT, after which the reaction was
stopped using 10% H2SO4. Absorbance was read at 450 nm.
Bilateral renal IRI
Syndecan-1–deficient mice16,26 and WT mice (both C57BL/6 back-
ground, syndecan-1–deficient mice backcrossed 46 generations)
were bred in VU University Medical Center facilities, the Nether-
lands. Age- and sex-matched mice were used in all experiments. The
animal ethics committee of the VU University Medical Center
approved all experiments. Briefly, renal pedicles were clamped for
25min using microaneurysm clamps through a midline abdominal
incision under anesthesia (0.07ml/10 g mouse of fentanyl citrate
fluanisone midazolam mixture containing 1.25mg/ml midazolam
(Roche Diagnostics, Basel, Switzerland), 0.08mg/ml fentanyl citrate,
and 2.5mg/ml fluanisone (Janssen Pharmaceutical)). After 25min
of ischemia, clamps were removed and kidneys were inspected for
restoration of blood flow. The abdomen was closed in two layers;
mice received s.c. analgesic (50 mg/kg buprenorphin (Temgesic;
Schering-Plough, Kenilworth, NJ)) and were allowed to recover
from surgery under a warm lamp. Sham-operated mice underwent
the same procedure without clamping and were killed 1 day after
surgery. IRI mice were killed at indicated time points and blood was
taken by cardiac puncture. Kidneys were removed, and one half was
snap-frozen, and one half was formalin-fixed and paraffin-
embedded for (immuno)histology.
Renal IRI histology and scoring
Formalin-fixed kidney sections (4mm) were stained with periodic
acid–Schiff ’s reagent and hematoxylin according to the routine
protocol to determine tubular damage. For specific detection of
monocytes/macrophages, acetone-fixed (10min RT) tissue sections
were rehydrated in PBS, blocked with PBSþ 5% normal goat serum
(10min RT), incubated with anti-monocyte/macrophage F4/80 (1 h
RT), and subsequently with anti-rat Alexa 488-labeled secondary
antibody. For specific detection of myofibroblasts, a-smooth muscle
actin staining was performed by incubating the sections with mouse
anti-smooth muscle actin (1 h RT), and subsequently with goat anti-
Mouse IgG2a peroxidase–labeled secondary antibody, followed by
the TSATM tetramethylrhodamine system (PerkinElmer LAS,
Waltham, MA). Immunofluorescence stainings were scanned by
using TissueFAXS (TissueGnostics GmbH, Vienna, Austria) and 15
digital photographs were taken (original magnification  200) from
renal cortex and outer medulla per kidney (30 photos for left and
right kidney together), using n¼ 7 mice per group per time point.
The total area stained was quantified using ImageJ 1.41 (Rasband,
W.S., ImageJ, US National Institutes of Health, Bethesda, MD), which
was downloaded from http://rsb.info.nih.gov/ij/download.html. Ki67
(Ab 15580, Abcam, Cambridge, UK) staining was performed on 4%
formaldehyde-fixed cryosections. Endogenous peroxidase activity was
blocked by using 0.01% H2O2 in PBS, followed by blocking with 10%
normal mouse serum. Primary antibody was incubated overnight at 4 1C,
followed by peroxidase-labeled goat anti-rabbit IgG, and peroxidase-
labeled rabbit anti-goat IgG, and 3-amino-9-ethylcarbazole. Quantifica-
tion was performed on 10 cortical fields/kidney at  20 original
magnification. Indicated is the mean number of Ki67-positive tubular
nuclei per high-power field per mice (left and right kidney together).
Statistical analysis
Data were analyzed using Kruskal–Wallis test with pairwise
comparisons (P-values adjusted for multiple comparisons), Spear-
man’s rank correlation test, Student’s t-test, or survival analysis by
log-rank test as indicated (PASW 18 statistics software, Chicago, IL). For
Kaplan–Meier analysis with log-rank test, groups of normal (as in control
kidneys; o30%) vs. increased (30–100%) TEC syndecan-1 were
compared. Loss of graft was defined by graft failure requiring dialysis
treatment or explantation of renal allograft. P-values of o0.05 were
considered to be statistically significant.
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